66 results about "Neurotransmission" patented technology

Disclosed are methods of improving treatment adherence and compliance after discontinuation of incretin-based therapies, such as GLP-1 and / or GIP agonists, using pharmacotherapies comprising the disclosed therapeutic compounds and combinations. In some aspects, methods include treatment of psychological factors affecting other medical conditions (PFAOMC) following the administration of incretin-based therapies to treat obesity or hyperglycemia, and related disorders. In some aspects, disclosed pharmacotherapies for use in the methods include agents that modulate monoaminergic neurotransmission, administered alone or together, such as in disclosed combinations having advantageous synergistic effects.

A composition of a compound represented by FIGS. 1A-1E for use in treating a medical disorder. A method of changing neurotransmission, by administering a pharmaceutically effective amount of composition to a mammal of a compound represented by FIGS. 1A-1E and inducing psychoactive effects in the mammal. A method of treating a patient having adverse reactions to psychedelics or entactogens, by administering a pharmaceutically effective amount of composition to the patient of a compound represented by FIGS. 1A-1E and avoiding adverse effects present with psychedelics or entactogens.

A composition of a compound represented by FIGURES 1 A-1 E for use in treating a medical disorder. A method of changing neurotransmission, by administering a pharmaceutically effective amount of composition to a mammal of a compound represented by FIGURES 1 A-1 E and inducing psychoactive effects in the mammal. A method of treating a patient having adverse reactions to psychedelics or entactogens, by administering a pharmaceutically effective amount of composition to the patient of a compound represented by FIGURES 1 A-1 E and avoiding adverse effects present with psychedelics or entactogens.

Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

Provided are compounds of Formula I and Formula II, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I and Formula II are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

Methods and systems for treating sleep disordered breathing and assessing and improving efficacy of treatment of sleep disordered breathing re disclosed herein. According to some embodiments, the present technology includes a method of treating sleep disordered breathing with a neuromodulation system at least partially implanted in a patient having an airway compromised by an obstruction. The method includes delivering stimulation energy to a target nerve in the patient using an electrode of the neuromodulation system, wherein the target nerve is associated with patency of the airway, receiving sensor data from a sensor arrangement of the neuromodulation system, wherein the sensor data is indicative of airflow in the airway proximal to the obstruction, and assessing efficacy of the stimulation energy based at least in part on the received sensor data.

Provided are compounds of Formula I and Formula II, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I and Formula II are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

Provided are compounds of Formula I and Formula II, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I and Formula II are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

Device / system that provides pain relief by delivering stimulation that neither generates action potentials nor completely blocks neural transmission (in the peripheral nerve). The present teachings provide relief by modulating release of neurotransmitters in peripheral nerves to cause neuromodulation at the level of the peripheral nerve (modulation of neural signals in the peripheral nerve). The present teachings provide relief by modulating release of neurotransmitters in peripheral nerves to cause neuromodulation at the level of the peripheral nerve (modulation of neural signals in the peripheral nerve) to alter the frequency of physiologically generated neural transmission.

The present invention provides a method and pharmaceutical composition for treating overactive bladder (OAB) and / or bladder pain syndrome (BPS) comprising a viral expression vector carrying a transcription cassette containing a transgene that inhibits / silences neurotransmission or synaptic transmission of an afferent neuron.

The present invention is directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives, advantageously for use in the prevention or treatment of neurological, psychiatric and sleep disorders and diseases in which central orexin neurotransmission is impaired or in which central and peripheral orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds for use in the prevention and / or treatment of neurological disorders and diseases. The present invention is also directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives and the use of these compounds as medicaments.

An implantable stimulation system is provided having a stimulation unit coupled to a programmable controller, a stimulation circuit, and an electrode array disposed on a pair of flexible blades for selectively stimulating at least one pelvic nerve, such as a cavernous nerve. The implantable stimulation system may be programmed to run a first sequence of stimulation pulses, the first stimulation pulse sequence corresponds to a first pattern for inducing a rapid erection reaction to achieve sexual behavior and potential ejaculation, a second pattern for inducing a rapid erection reaction sufficient to facilitate a medical procedure, such as applying a catheter, a third neurological rehabilitation stimulation pattern for restoring neurotransmission to treat urinary incontinence and / or intestinal dysfunction, and / or a fourth penis rehabilitation pattern for reducing penis fibrosis. A method of operating the system is also provided.

In nerve diseases, cell dysfunction due to amyloid aggregate accumulation in nerve cells has attracted attention, but dysfunction of nerve axons responsible for neurotransmission is also considered to be one of the causes. However, no therapeutic agent that focuses on the repair and maintenance of nerve axons has been found. An object of the present invention is to provide a therapeutic agent that activates oligodendrocytes having a function of preserving nerve axons.SOLUTION: Transcriptome analysis with a psychotropic drug is carried out using an oligodendrocyte marker as an indicator, and it is found that the combined use of DPZ and NFN characteristically increases the expression of a transcriptional factor OLIG1 inducing the differentiation-maturation of the oligodendrocyte. Moreover, the drug concentration at this time was much lower than the expected clinical dose. The combined use of NFN and DPZ was observed to improve spatial memory in the mouse Y-maze test. The combination of NFN and DPZ can provide a novel treatment for cognitive and memory functions associated with neurological disorders.SELECTED DRAWING: None

This invention belongs to the field of biomedicine and discloses estradiol derivatives or pharmaceutically acceptable salts thereof with the structure shown in Formula I: R is selected from R1, which is selected from F, Cl, Br, and I; L is selected from straight-chain or branched alkyl groups with 2 to 10 carbon atoms. This invention also discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs for treating depression and anxiety. Furthermore, this invention discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs targeting ERβ / SERT for treating depression and anxiety. The estradiol derivatives of this invention can simultaneously and effectively inhibit SERT and activate ERβ, thereby synergistically enhancing serotonergic neurotransmission and regulating neuroplasticity, and enhancing antidepressant efficacy through multi-target synergistic effects.

The present invention provides N-substituted phenylalkylamines, methods of making the same, and methods of using such compounds, e.g., as receptor probes, as neurotransmission modulators, and as therapeutic agents, e.g., as central nervous system drugs. Also provided are pharmaceutical compositions and methods for their use in the treatment of certain diseases, such as serotonin neurotransmitter diseases, mental health disorders, and ion channel mediated diseases, such as seizure disorders.

The present disclosure relates to the use of compounds of formula (I), compounds of formula (II), and related analogs for enhancing neurogenesis, enhancing neurite outgrowth, enhancing nerve growth, nerve connectivity, synaptic density, dendritic spine density, dendritic spine size, and excitatory neurotransmission in the brain (e.g., in the medial prefrontal cortex), and to methods of enhancing neurogenesis, enhancing neurite outgrowth, enhancing nerve growth, nerve connectivity, synaptic density, dendritic spine density, dendritic spine size, and excitatory neurotransmission in the brain (e.g., in the medial prefrontal cortex). And other methods and uses related thereto.

The present invention provides a method and a pharmaceutical composition for the treatment of overactive bladder (OAB) and / or bladder pain syndrome (BPS) comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting / silencing neurotransmission or synaptic transmission of afferent neurons.

Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

The invention concerns a compound of formula (I) (I) R1═H, —CH3 or acyl group, preferably R1═—CH3R2═H or halogen atom selected in the group consisting of: F, Cl, Br, I, preferably R2═H or a pharmaceutically acceptable isomer, salt and / or solvate thereof, for use in preventing and / or treating neurodegenerative diseases when central muscarinic neurotransmission is compromised, wherein said neurodegenerative disease is selected in the group consisting of Alzheimer's Disease (AD), vascular dementia, Dementia with Lewy bodies (DLB), mixed dementia, frontotemporal lobar degeneration (FTLD), and Parkinson's disease (PD).

Provided herein are compounds of formula I, their preparation methods, their use as medicines, and pharmaceutical compositions containing them and intermediates used in their preparation.The compounds of formula I are useful, for example, for modulating dopamine and serotonin neurotransmission, and for treating disorders that may benefit from them, for example, schizophrenia and depression.

A composition of compounds generally represented by Figure 1A for use in substance adjuvant therapy. A method of altering neurotransmission by administering to a mammal a pharmaceutically effective amount of a compound of Figure 1A, interacting with the serotonin 5-HT2A receptor and inducing a psychoactive effect in the mammal, particularly in a human body. A method of treating a subject by administering to the subject a pharmaceutically effective amount of a compound of Figure 1A and treating the subject.

The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and agents which promote brain health and / or immune health. The invention also relates to such compositions, for use for the treatment or prevention of diseases, disorders and conditions, and for use in non-therapeutic treatments. Example of agents which promote brain health include brain protective agents (for example phosphatidylserine, phosphatidylcholine and / or choline), agents that enhance neurotransmission (for example a nootropic, for example ergothioneine, huperzine, aGPC, taurine and / or L-theanine), agents that promote neurogenesis (for example selenium); and brain essential nutrients (example Vitamin B6, B9, B12, magnesium salts, folic acid and / or L-methylfolate). Examples of agent which promote immune health include quercetin, Elderberry or an extract thereof; a selenium salt; and / or a zinc salt.

This application provides compounds of Formula I described herein, methods for their preparation, their use as pharmaceuticals, pharmaceutical compositions comprising them, and intermediates used in their preparation. Compounds of Formula I can be used, for example, to regulate dopamine and serotonin neurotransmission, and to treat conditions from which they may benefit, such as schizophrenia and depression.

The present invention relates to dihydroquinazoline, dihydrobenzothiazine and dihydrobenzoxazine derivatives for use in the prevention or treatment of neurological, psychiatric, sleep disorders and diseases, advantageously in which central orexin neurotransmission is impaired or in which central and peripheral orexin receptors are involved. The invention also relates to pharmaceutical compositions comprising these compounds, their use for the prevention and / or treatment of nervous system disorders and diseases. The invention also relates to dihydroquinazoline, dihydrobenzothiazine and dihydrobenzoxazine derivatives, and to the use of these compounds as medicaments.

In some aspects, the disclosure relates to certain siloxine and silosibin analogs, such as tryptamine containing a 4-(2-hydroxyalkyl)-7-alkyl or 4-(2-methoxyalkyl)-7-alkyl substitution on the indole benzene ring. In some aspects, the disclosure relates to pharmaceutical compositions containing these compounds, and methods of using such compounds and compositions to modulate neurotransmission (e.g., serotonergic neurotransmission), modulate neuroplasticity, and treat medical conditions (e.g., inflammatory diseases and conditions). Formula (1)

The invention provides high-protein low-sugar milk shake capable of improving memory and a preparation method of the high-protein low-sugar milk shake. The high-protein low-sugar milk shake comprises the following components: fresh milk, soybean protein isolate, dihydroquercetin powder, maltodextrin, resistant dextrin, ginseng powder, coconut milk powder, erythritol, multivitamins, mineral powder, folic acid, N-acetylneuraminic acid and peach gum. Compared with existing milkshake which is single in nutritional ingredient, the dihydroquercetin powder is formed by modifying dihydroquercetin through amino acid, biocompatibility and water solubility are obviously improved, and the dihydroquercetin milkshake has good free radical scavenging and anti-inflammatory effects and promotes growth of neurons. If the traditional Chinese medicine composition is used, the synthesis of acetylcholine in the brain is promoted, the neurotransmission effect is enhanced, and the memory is improved by cooperating with dihydroquercetin.

This disclosure relates in some aspects to novel compounds comprising a substituted benzylpyrrolidine pharmacophore, and analogs thereof. In some aspects, the disclosure further relates to compositions containing the compounds, methods of synthesizing the compounds, and methods of using the compounds. In some aspects, the compounds are useful as therapeutic agents for treating medical conditions, for example by modulating neurotransmission.

The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting / silencing neurotransmission or synaptic transmission of afferent neurons.

Methods of use, pharmaceutical formulations, and labeled versions of compounds are provided of compounds that penetrate the blood-brain barrier and influence the balance of excitatory versus inhibitory neurotransmission by enantiomer selective modulation of glutamate and GABA metabolism. In some embodiments, a glutamatergic false neurotransmitter is S-2-methylglutamate (S-2MeGlu). In some embodiments a GABAergic false neurotransmitters is R-4 aminopentanomic acid (4APA) or S-4 aminopentanomic acid (S-4APA), with high penetration of the blood brain barrier and low toxicity, therein providing useful pharmacologic or imaging agents.